We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Elicio Therapeutics, Inc., formerly Angion Biomedica Corp., is a clinical-stage biotechnology company. The Company is engaged in developing a pipeline of immunotherapies for the treatment of cancer and other diseases. It provides a platform, amphiphile (AMP) that delivers immuno therapeutics directl... Elicio Therapeutics, Inc., formerly Angion Biomedica Corp., is a clinical-stage biotechnology company. The Company is engaged in developing a pipeline of immunotherapies for the treatment of cancer and other diseases. It provides a platform, amphiphile (AMP) that delivers immuno therapeutics directly to the lymph nodes (brain center) of the immune system. The Company's lead product candidate, ELI-002, is being developed to treat cancers driven by kirsten rat sarcoma (KRAS). It is conducting a Phase I/II clinical trial of ELI-002 (AMPLIFY-201). The Company is also evaluating the use of ELI-004, a universal AMP-modified clinical practice guidelines (CpG) adjuvant to treat or prevent additional diseases. The Company provides anaplastic lymphoma kinase (ALK) program to identify an internal development candidate. The Company conducts assessments for using ELI-004 to induce immune responses targeting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Show more
BOSTON, April 25, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel...
68% of patients treated with ELI-002 developed cytotoxic mKRAS-specific CD4+ T cells84% of patients treated with ELI-002 developed cytotoxic mKRAS-specific CD8+ T cellsThe majority of...
ELI-002 2P clinical immunogenicity data were accepted for a poster presentation at the AACR Annual Meeting 2024ELI-007 and ELI-008 preclinical data were accepted for a poster presentation at the...
BOSTON, March 18, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel...
BOSTON, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel...
Published data shows lymph node-targeted Amphiphile (“AMP”)-peptide and CpG combination with TCR-T cell therapy led to complete eradication and durable responses against established murine solid...
AMPLIFY-7P study builds on preliminary positive findings from the 2-peptide formulation of ELI-002 published in Nature Medicine demonstrating tumor biomarker reduction, with strong T cell...
BOSTON, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.39 | 4.53488372093 | 8.6 | 9.9 | 8.34 | 33736 | 9.36977247 | CS |
4 | 2.16 | 31.6251830161 | 6.83 | 10.4365 | 6.522 | 58717 | 8.92120639 | CS |
12 | 4.49 | 99.7777777778 | 4.5 | 10.4365 | 2.96 | 57225 | 6.60676856 | CS |
26 | 2.76 | 44.3017656501 | 6.23 | 10.57 | 2.96 | 75163 | 5.86762627 | CS |
52 | -5.01 | -35.7857142857 | 14 | 24.39 | 2.96 | 55485 | 7.63712087 | CS |
156 | -5.01 | -35.7857142857 | 14 | 24.39 | 2.96 | 55485 | 7.63712087 | CS |
260 | -5.01 | -35.7857142857 | 14 | 24.39 | 2.96 | 55485 | 7.63712087 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions